UNSPSC 51151624: Butinoline

This classification denotes an antimuscarinic agent with the molecular formula C20H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G216926E9T, chemically known as 1,1-diphenyl-4-pyrrolidino-1-yl but-2-yn-1-ol but generally known as butinoline, which bears US NIH Compound Identifier 68943. European Medicines Agency schedules Butinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06020MIG. The term BUTINOLINE is an International Non-Proprietary Name.

UNSPSC 51151624 Butinoline is a Commodity code that encompasses pharmaceutical products and drug-related supplies procured by state and local health agencies. Recent opportunities show state and local governments buying naloxone (opioid overdose reversal medication) and drug deactivation systems through this code. Seminole County, Florida is soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to support community health initiatives. The Texas Health and Human Services Commission has issued an RFI to gather vendor capabilities for a Therapeutic Pharmacy Initiative focused on direct-to-manufacturer prescription fulfillment. Issuing bodies under this code include county health departments and state HHS agencies, typically supporting public health programs and pharmacy benefit management. The work involves procurement of finished pharmaceutical products and related health-support systems for distribution to public health facilities and community programs.

Recent activity centers on Florida and Texas. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) represents a straightforward competitive bid for ongoing pharmaceutical supply with a two-year initial term and one-year renewal option, requiring electronic submission, E-Verify compliance, drug-free workplace certification, and standard commercial insurance. The Texas HHS Commission RFI (HHS0017013, response due April 3, 2026) is exploratory market intelligence gathering on direct contracting models for prescription fulfillment, intended to inform a future formal RFP. This preliminary RFI suggests the state is evaluating vendor capabilities for negotiated net pricing models and outcomes-based agreements outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity specifies explicit set-asides for disadvantaged enterprises, though both require standard vendor compliance and authorization to work in the United States.